Protagonist Therapeutics, Inc.
PTGX
$96.75
$4.394.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -95.64% | 0.79% | 33.09% | -88.89% | 184.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.64% | 0.79% | 33.09% | -88.89% | 184.40% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -95.64% | 0.79% | 33.09% | -88.89% | 184.40% |
| SG&A Expenses | 27.70% | 9.57% | 11.77% | -21.27% | 11.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.77% | 10.85% | 10.77% | -2.08% | 18.69% |
| Operating Income | -139.72% | -11.98% | -8.37% | -109.36% | 450.05% |
| Income Before Tax | -132.71% | -16.98% | -10.57% | -105.53% | 388.98% |
| Income Tax Expenses | -66.53% | -- | 125.44% | -- | -- |
| Earnings from Continuing Operations | -133.71% | -18.46% | -13.57% | -105.62% | 381.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -133.71% | -18.46% | -13.57% | -105.62% | 381.70% |
| EBIT | -139.72% | -11.98% | -8.37% | -109.36% | 450.05% |
| EBITDA | -139.39% | -11.74% | -8.26% | -109.23% | 444.70% |
| EPS Basic | -132.81% | -14.73% | -9.63% | -105.43% | 366.67% |
| Normalized Basic EPS | -131.84% | -13.28% | -6.74% | -105.35% | 373.77% |
| EPS Diluted | -135.17% | -14.81% | -10.00% | -105.83% | 351.31% |
| Normalized Diluted EPS | -133.93% | -13.28% | -6.74% | -105.59% | 354.97% |
| Average Basic Shares Outstanding | 2.73% | 3.25% | 3.60% | 3.46% | 3.21% |
| Average Diluted Shares Outstanding | -3.58% | 3.25% | 3.60% | -0.99% | 7.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |